NQO1 Antibody (YA3813)(PBS only)

NQO1 (NAD (P) H:quinone oxidoreductase 1) is a cytosolic flavoprotein that catalyzes the obligate two-electron reduction of endogenous and exogenous quinones to hydroquinones, thereby limiting semiquinone formation, redox cycling, and reactive oxygen species generation^[1][2]. Through this catalytic activity, NQO1 functions as a major cellular defense enzyme that supports redox homeostasis and protects cells from oxidative and electrophilic stress^[1][3]. Mechanistically, NQO1 is a prominent downstream target of the Keap1-Nrf2-ARE signaling pathway, and its transcription is strongly induced during oxidative stress and xenobiotic exposure, linking environmental stress responses to cytoprotective gene expression programs^[3][4]. In disease contexts, NQO1 is frequently overexpressed in multiple solid tumors, including lung, breast, liver, colon, and pancreatic cancers, where elevated expression is associated with adaptation to oxidative stress and altered responses to therapeutic agents^[3][5][6]. Compared with the related isoform NQO2, NQO1 is the predominant stress-inducible quinone reductase and utilizes NADH or NADPH as reducing cofactors, whereas NQO2 exhibits distinct cofactor preferences and biological regulation, supporting nonredundant cellular functions^[7][6]. For experimental applications, NQO1 is widely used as a model enzyme for investigating redox regulation, quinone metabolism, and cytoprotective signaling pathways, while the inhibitor dicoumarol remains a commonly employed pharmacological tool for probing NQO1-dependent biological mechanisms^[2][6].